Options and Challenges for Ethical Assessment in the Clinical Trial Regulation Proposal
|
|
- Laura Lamb
- 6 years ago
- Views:
Transcription
1 EFGCP Workshop on Options and Challenges for Ethical Assessment in the Clinical Trial Regulation Proposal Road Map Initiative for Clinical Research in Europe Husa President Hotel, Brussels, Belgium 7 & 8 November 2012 Organised by where science & ethics meet European Forum for Good Clinical Practice In Collaboration with - conferences@efgcp.eu
2 Introduction In July 2012, the European Commission adopted a proposal for a Regulation on Clinical Trials to resolve a number of problems identified with the current legislation. In the legislative process this proposal is now subject to discussions by the European Parliament and the Council representing the 27 Member States and in parallel by all stakeholders affected by it. One of the key changes proposed concerns the assessment and decision system for clinical trial applications. In the proposal the Commission defines the regulatory environment and the objectives to be achieved. Fulfilling these requirements will need a critical review of the options for national clinical trial approval systems in the Member States and the types of collaboration between competent authorities and research ethics committees. The workshop is meant to provide a platform for a constructive discussion on the ways research ethics committees could be involved and ensure an appropriate ethical assessment of the clinical trials in future. What is the background for the new legislation? The current legislation has been criticised by nearly all stakeholders involved into clinical trials. This led to several hearings, workshops and two consultation rounds launched by the European Commission, to identify the extent of the problem and the reasons for the decrease of number of clinical trials in Europe. In these discussions and exchanges unnecessary bureaucracy, duplication of submission dossier review procedures by competent authorities and ethics committees, especially for multi-national clinical trials and the current complex authorisation and supervision processes had been highlighted as a reason for Europe to loose attractiveness for research and development: According to the Commission s impact assessment since the implementation of the clinical trials directive in 2004, the number of clinical trials activated in Europe has dropped by 25% in a research environment which has increasingly be subject to global competition. This decreasing number is equally worrying different communities which are engaged in or benefit from clinical trials: academia, clinicians, patients and pharmaceutical industry and the European society as a whole. The absence of an efficient regulatory framework is one significant reason for this. Demanding regulatory requirements have increased the costs of clinical trials. This applies in particular for international clinical trials, which by their nature are much more impacted by administrative burden of the current framework resulting in prolonged trial activation timelines and unjustified complexity of their set-up. What did stakeholders call for? What is needed is a balanced and efficient approach that allows fast access for patients but also meets highest safety and quality standards for the protection of trials subjects. During the consultations and discussions broad consensus had been achieved between academic and commercial sponsors on the need for an EU harmonised and streamlined clinical trial authorisation system, involving a single submission procedure primarily for multinational clinical trials. This had been communicated through the Road Map Initiative for Clinical Research in Europe in What did the Commission propose? The proposed regulation sets clear objectives and timelines for the assessment of and decision on clinical trials by Member States while respecting international guidelines such as set by the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) and World Medical Association s Declaration of Helsinki. Since Member States have the exclusive competence to organise responsibilities at a national level and the EU has no right to legislate in this area, the proposal clearly isolates items relevant to the national competent authorities and ethics committees. Therefore, it will be up to each Member State to legislate the organisation of national authorities and ethics committees while respecting regional and cultural aspects. The proposed concept for submission, assessment and decision process for a clinical trial application includes the single submission for all Member States through an EU electronic portal including a clear and harmonized list Page 2 of 8
3 of documents to be submitted. The subsequent assessment procedure proposed would enable trial sponsors to obtain approvals from all participating member states within days (depending on the nature of the trial). These timeline are reasonably competitive within the global context of R&D. The aim of this workshop is to start a dialogue on practical implications of the Commission s proposal for ethics committees on the following assumptions: Each Member State will issue the authorization to run a clinical trial on the basis of a coordinated assessment integrating the scientific-technical review by competent authorities as well as the result of the national ethical assessment. The mechanism of such an integration may require different solutions from one country to another. Sponsors will be able to start clinical trials immediately after notification of the decision on the clinical trial by a particular Member State The workshop provides an opportunity to reflect upon, exchange opinion and develop creative solutions on how to integrate all the aspects into one decision per Member State within the proposed timelines without compromising the established scientific/ethical review standards and the level of patient protection in all countries involved in the trial. Programme Committee Sabine Atzor Isabelle Clamou Jacques Demotes Jan Geissler Angelika Joos Ingrid Klingmann Anastassia Negrouk Fabien Peuvrelle Nick Sykes Faculty Sabine Atzor Olivier Chassany Isabelle Clamou Marek Czarkowski Jacques Demotes Stefan Führing F. Hoffmann-La Roche, Switzerland European Federation of Pharmaceutical Industries and Associations (EFPIA), Belgium European Clinical Research Infrastructures Network (ECRIN), INSERM, France European Patients' Academy on Therapeutic Innovation (EUPATI), Patvocates, European Forum for Good Clinical Practice (EFGCP), Germany Merck Sharp & Dohme, Belgium Pharmaplex, European Forum for Good Clinical Practice (EFGCP), Belgium European Organisation for Research and Treatment of Cancer (EORTC), Belgium Celgene, Switzerland Pfizer, United Kingdom F. Hoffmann-La Roche, Switzerland Assistance Publique - Hôpitaux de Paris, France European Federation of Pharmaceutical Industries and Associations (EFPIA), Belgium Center of Bioethics of the Supreme Medical Council, Poland European Clinical Research Infrastructures Network (ECRIN), INSERM, France DG Sanco, European Commission Page 3 of 8
4 Jan Geissler David Haerry Susanna Fürst Angelika Joos Ingrid Klingmann Petra Knupfer Flaminia Macchia Françoise Meunier Greet Musch Anastassia Negrouk European Patients' Academy on Therapeutic Innovation (EUPATI), Patvocates, European Forum for Good Clinical Practice (EFGCP), Germany European AIDS Treatment Group (EATG), Switzerland (to be invited) Central Ethics Committee, Hungary Merck Sharp & Dohme, Belgium Pharmaplex, European Forum for Good Clinical Practice (EFGCP), Belgium Ethics Committee Baden-Württemberg, European Forum for Good Clinical Practice (EFGCP), Germany (to be invited) EURORDIS, Belgium European Organisation for Research and Treatment of Cancer (EORTC), Belgium FAMHP, Belgium European Organisation for Research and Treatment of Cancer (EORTC), Belgium Fabien Peuvrelle Celgene, Switzerland E. Singer University Hospital Vienna, Austria Nick Sykes Pfizer, United Kingdom Janet Wisely National Research Ethics Service (NRES), United Kingdom Workshop Venue Husa President Hotel Boulevard du Roi Albert II, Brussels, Belgium Tel.: Fax: info.president@husa.es Website: Workshop Language The language of the workshop will be English. Registration & Information OPEN EVENT conferences@efgcp.eu or visit Page 4 of 8
5 Agenda DAY 1 10:00 Registration & Welcome Coffee 10:30 Welcome, General Introduction & Aim of the Day: Ingrid Klingmann, Pharmaplex, European Forum for Good Clinical Practice (EFGCP), Belgium SESSION 1: The Proposed Clinical Trial Approval Process 10:40 Presentation of the Commission Proposal Stefan Führing, DG Sanco, European Commission 11:00 Academia s considerations Anastassia Negrouk, European Organisation for Research and Treatment of Cancer (EORTC), Belgium 11:15 Industry s considerations Isabelle Clamou, European Federation of Pharmaceutical Industries and Associations (EFPIA), Belgium 11:30 CROs considerations Representative, Association of Clinical Research Organisations (ACRO) 11:45 A National Competent Authority s considerations Greet Musch, FAMHP, Belgium 12:00 Ethics committees considerations Representative, EURECNet 12:15 Patient organisations considerations Flaminia Macchia, EURORDIS, Belgium 12:30 Panel Discussion: Is the Regulation Proposal Ensuring Patient Protection? 13:00 Lunch Break Page 5 of 8
6 SESSION 2: Ethics Committees View on Opportunities and Challenges in Adapting the Ethical Review Process to the Commission Proposal (10 min presentation, 10 min Q&A) 14 :00 View from Netherlands 14:20 View from Germany 14:40 View from Hungary Susanna Fürst, Central Ethics Committee, Hungary 15:00 View from UK Janet Wisely, National Research Ethics Service (NRES), United Kingdom 15:20 View from France Olivier Chassany, Assistance Publique - Hôpitaux de Paris, France 15:40 View from Italy 16:00 Coffee Break SESSION 3: Options, Opportunities and Concerns for Joined Part I Decision Making by Competent Authorities and Ethics Committees 16:30 Panel and Open Forum Discussion 18:00 End of Day 1 18:15 Walking Dinner Page 6 of 8
7 08:30 Welcome Coffee DAY 2 SESSION 4: Organisation and Collaboration Between Competent Authorities and Ethics Committees in the Part II Assessment Introduction & 09:00 How could this work in Poland? Marek Czarkowski, Center of Bioethics of the Supreme Medical Council, Poland 09:10 How could this work in Denmark? 09:20 How could this work in Austria? E. Singer, University Hospital Vienna, Austria 09:30 How could this work in Lithuania? 09:40 How could a Harmonised Investigator Certification Contribute to Site quality? An Investigator s View 09:50 How could a Harmonised Investigator Certification Contribute to Site quality? An Auditor s View 10:00 Patient Organisations Needs and Expectations from Such a Review? 10:10 CRO s Needs and Expectations from Such a Review? 10:20 Discussion: Can the Proposed Timelines be Achieved? 11 :15 Coffee Break Page 7 of 8
8 SESSION 5: Where Are Areas Where Ethics Committees Could Collaborate in Europe to Achieve a More Efficient Ethical Review Process? 11:45 Overview over Current National Site Assessment and Contractual Arrangement Approaches 12:15 Panel and Open Forum Discussion: Topics Like: Site Accreditation, Investigator Certification, Subject Compensation, Ethics Committee Training Programmes, Trans-National EC Working Groups, etc. 13:30 Conclusion and Next Steps 13:45 End of the Workshop 13:45 Farewell Lunch Page 8 of 8
within April Organised by the With
EFGCP Multi-Stakeholder Workshop & Discussion on How to Ensure Optimal Ethical Review within the New Clinical Trials Regulation? Wheree do we currently stand with the implementation in different Member
More informationwithin April Organised by the
EFGCP Multi-Stakeholder Workshop &Discussion on How to Ensure Optimal Ethical Review within the New Clinical Trials Regulation? Wheree do we currently stand with the implementation in different Member
More informationA Multi-Stakeholder Workshop of the Joint EFGCP-MedTech Europe Medical Technology Working Party on
A Multi-Stakeholder Workshop of the Joint EFGCP-MedTech Europe Medical Technology Working Party on Mitigating Risks in the Lifecycle of Medical Devices: Options and Challenges in Building Clinical Evidence
More informationTaking forward reform of the EU Clinical Trials Directive. Introduction
Taking forward reform of the EU Clinical Trials Directive Introduction Implementation of the Clinical Trials Directive (CTD), intended to harmonise authorisation of EU clinical trials on medical products,
More informationEUPATI 2013 CONFERENCE EUPATI: A VISION FOR 2020
EUPATI 2013 CONFERENCE EUPATI: A VISION FOR 2020 19 April 2013, Hilton Rome Airport Hotel, Rome Airport Fiumicino, Italy Introduction The EUPATI consortium is delighted to announce its first EUPATI conference
More informationResearch Ethics Committees and Ethical Review in Europe
Multidisciplinary Workshop on Research Ethics Committees and Ethical Review in Europe 19 th January 2010, Barcelona, Spain On behalf of the Road Map Initiative for Clinical Research in Europe FINAL REPORT
More informationWRITTEN SUBMISSION ON THE OPERATION OF THE CLINICAL TRIALS DIRECTIVE (DIRECTIVE 2001/20/EC) AND PERSPECTIVES FOR THE FUTURE
WRITTEN SUBMISSION ON THE OPERATION OF THE CLINICAL TRIALS DIRECTIVE (DIRECTIVE 2001/20/EC) AND PERSPECTIVES FOR THE FUTURE ECRIN (European Clinical Research Infrastructures Network) EORTC (European Organization
More informationExplore Ways to Enhance Collaboration Between Key Players
Joint EFGCP / DIA / EMA Better Medicines for Children Conference 2014 on Explore Ways to Enhance Collaboration Between Key Players 30 th September & 1 st October 2014 EMA, London, United Kingdom Organised
More informationClinical Trials Environment EU Legislation: Ausblick auf die neue Gesetzgebung für klinische Prüfungen
The Future of the Regulatory Berlin, 31.05.2013 Clinical Trials Environment EU Legislation: Qualifizierungstag für Study Nurses Ausblick auf die neue Gesetzgebung für klinische Prüfungen Dr. med. Ingrid
More informationENVIRONMENTAL RISK ASSESSMENTS: EU CLINICAL TRIALS WITH GMO-BASED ATMPS ANN GORMAN, AMGEN LTD, UK 16 DECEMBER 2016
ENVIRONMENTAL RISK ASSESSMENTS: EU CLINICAL TRIALS WITH GMO-BASED ATMPS ANN GORMAN, AMGEN LTD, UK 16 DECEMBER 2016 SIMPLIFIED DEFINITIONS Genetically Modified Organism (GMO)? An organism, e.g virus, plant,
More informationReview of EU Clinical Trial Directive. 15 May 2012 Mike Beckers Sidley Austin LLP, Brussels
BEIJING BRUSSELS CHICAGO DALLAS FRANKFURT GENEVA HONG KONG LONDON LOS ANGELES NEW YORK PALO ALTO SAN FRANCISCO SHANGHAI SINGAPORE SYDNEY TOKYO WASHINGTON, D.C. Review of EU Clinical Trial Directive 15
More informationEuropean Pharmaceutical Policy: Access for Patients or Improving Competitiveness
European Pharmaceutical Policy: Access for Patients or Improving Competitiveness The s Vision Dr Stefaan Van der Spiegel Policy Officer, Unit F5 DG Enterprise and Industry Study day OSE / RIZIV-INAMI Brussels,
More informationImpact of the transposition of the European Clinical Trials Directive. CEMO, Paris 17 November 2004
Impact of the transposition of the European Clinical Trials Directive CEMO, Paris 17 November 2004 Dr Martine Dehlinger-Kremer VP Regulatory Affairs International Agenda Overview of key areas of Directive
More informationRevision of the Clinical Trials Directive - Key issues and next steps
Revision of the Clinical Trials Directive - Key issues and next steps EURECNET Conference Bratislava, 12-13 April 2012 Fabio D Atri Unit D6 Medicinal products quality, safety and efficacy Directorate-General
More informationThe European Commission s strategy on Corporate Social Responsibility (CSR) : achievements, shortcomings and future challenges
The European Commission s strategy on Corporate Social Responsibility (CSR) 2011-2014: achievements, shortcomings and future challenges Fields marked with * are mandatory. 1 Introduction - Background and
More informationThe EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Bulgaria
The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Bulgaria Question 1: What laws or regulations apply to an application for conducting a clinical
More informationThe EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Ireland
The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Ireland Question 1: What laws or regulations apply to an application for conducting a clinical
More informationEU Perspective on Regulatory Issues for Biologics
Oncology Biologics Development Primer 29 February 2008 Robert Charnas Disclosure Employee and shareholder of Amgen, Inc. Thousand Oaks, CA Worked in Basel, Switzerland for 19 Years and dealt with European
More informationDoes the European Clinical Trials Directive really improve clinical trial approval time?
British Journal of Clinical Pharmacology DOI:10.1111/j.1365-2125.2008.03246.x Does the European Clinical Trials Directive really improve clinical trial approval time? Hiddo J. Lambers Heerspink, Daniela
More informationENTR/F/2/SF D(2009) Assessment of the Functioning of the Clinical Trials Directive 2001/20/EC Public Consultation
Geschäftsstelle.. D- To European Commission Enterprise and Industry Directorate-General Consumer Goods Pharmaceuticals Via Mail Entr-pharmaceuticals@ec.europa.eu Heidelberg, January 9, 2010 ENTR/F/2/SF
More informationRe : EC Consultation Paper Revision of the variations regulations
Merck Sharp & Dohme (Europe) Inc. Lisette Vromans Clos du Lynx 5 Lynx Binnenhof Regulatory Policy Brussel 1200 Bruxelles EU & Most of World 32 2 776 6211 31 412 66 2755 Fax 31 412 66 2571 e-mail : lisette.vromans@merck.com
More informationEUROPEAN COMMISSION HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL
EUROPEAN COMMISSION HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL Health systems, medical products and innovation Medicines: policy, authorisation and monitoring PHARM 723 PHARMACEUTICAL COMMITTEE 18 October
More informationGenesis of the F-Gas Regulation
Genesis of the F-Gas Regulation ECSLA Fall Conference October 16-17,2012 Madrid Genesis of the F-Gas Regulation 2000-2000 First working group on F-gases set up by the Commission NL recommends to adapt
More informationComments on: Name of Organisation
Comments on: THE RULES GOVERNING MEDICINAL PRODUCTS IN THE EUROPEAN UNION VOLUME 10 - GUIDANCE DOCUMENTS APPLYING TO CLINICAL TRIALS HARMONISED REQUIREMENTS FOR NON INVESTIGATIONAL MEDICINAL PRODUCTS IN
More informationNETWORKING OF EUROPEAN REC`S. Dirk Lanzerath EUREC, Secretary General
NETWORKING OF EUROPEAN REC`S Dirk Lanzerath EUREC, Secretary General First steps of EUREC based on 2001 EC Directive on good clinical practice in the conduct of clinical trials on medicinal products for
More informationEUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. Health systems and products Medicinal products authorisations, EMA Head of Unit
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products authorisations, EMA Head of Unit PHARM 606 PHARMACEUTICAL COMMITTEE 28 March 2012 68 th meeting
More informationRe: Public Consultation Paper on the Regulation of Advanced Therapy Medicinal Products
ISCT HEAD OFFICE Suite 201 375 West 5 th Avenue Vancouver, BC Canada V5Y 1J6 Tel: 604-874-4366 Fax: 604-874-4378 isct@celltherapysociety.org www.celltherapysociety.org March 30, 2013 European Commission,
More informationTrack III: International Clinical Trials: Global Compliance Norms and EU Focus
Track III: International Clinical Trials: Global Compliance Norms and EU Focus EU Focus Emmanuelle Voisin, PhD Principal, Voisin Consulting May 2008 Rationale Clinical trials in EU important part of health
More informationSession 13: Prequalification Within the Context of Global Fund Procurements
Session 13: Prequalification Within the Context of Global Fund Procurements Established in 2002 Global Fund Attracts and disburses additional resources to prevent and treat AIDS, tuberculosis (TB), and
More informationRegulatory and ethics bodies involved in approval process for trials. National Ethics Committee; Agency for Data Protection;
Nutrition/InterventionaI - LUXEMBOURG Competent authority Contact Details Contact Name 1 Ministry of Health Phone +352 247-85592 / 96 Fax +352 24795615 Email General info@ ms.etat.lu Address Allée Marconi
More informationFederal agency for medicines and health products
Federal agency for medicines and health products The implementation of the EU CT Regulation : Overview of the different projects in progress Greet Musch KCE Symposium, 12 th October 2016 1: Overview of
More informationRegulatory Newsletter January - March 2014
Regulatory Newsletter January - March 2014 Introduction CROMSOURCE is committed to sharing our expertise with our clients and future clients. This reflects the first part of our Advise Agree Deliver motto!
More informationHighlights of the proposed Clinical Trials Regulation in Europe
Highlights of the proposed Clinical Trials Regulation in Europe Dr Daryl Rees 22 January 2013 Proposed Clinical Trials Regulation On 17July 2012, the Commission adopted the proposal for a "Clinical Trials
More informationEditor : Francoise SCHLEMMER Date : 09/03/2015 IMDRF, March 9 th 2015 REPORT Present : Hans-Heiner Junker Francoise SCHLEMMER
The European Association Medical Devices - Notified Bodies TEAM-NB A.I.S.B.L. Boulevard Frère Orban 35A B 4000 Liège BELGIQUE Tél.: + 32 (0)4 254 55 88 Fax: + 32 (0)4 254 55 89 E-mail: secretary@team-nb.org
More informationEU Clinical Trial Regulation A view from the Industry
Conference EU Clinical Trial Regulation EU Clinical Trial Regulation A view from the Industry Judith Creba, Executive Director, EU Regulatory Strategy, Novartis Pharma AG University of Basel, Law Faculty
More informationEUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL PUBLIC CONSULTATION
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Healthcare systems Health systems and products PUBLIC CONSULTATION Brussels, 31 July 2012 on the modalities of stakeholder consultation in the
More informationPublic Consultation on the European Solidarity Corps
Contribution ID: 2d9b4621-cc4d-4c64-a5af-13acac98b4fe Date: 31/03/2017 17:04:55 Public Consultation on the European Solidarity Corps Fields marked with * are mandatory. Introduction The European Solidarity
More informationPublic Consultation Paper: Assessment of the Functioning of the Clinical Trials Directive 2001/20/EC
Public Consultation Paper: Assessment of the Functioning of the Clinical Trials Directive 2001/20/EC National Institute for Health Research (NIHR CRN) and UKCRC Registered Clinical Trials Units Response
More informationRegulatory and ethics bodies involved in approval process. CA - Registration requirements for clinical trials
Nutrition - LUXEMBOURG Competent authority Contact Details Contact Name 1 Ministry of Health Phone +352 247-85592 / 96 Fax +352 24795615 Email General info@ ms.etat.lu Address Allée Marconi - Villa Louvigny
More informationThe new EU clinical trial regulation 536/2014 : Low interventional trials
The new EU clinical trial regulation 536/2014 : Low interventional trials KCE Greet Musch Brussels, 28 th November 2017 Agenda: 1: Legal framework EU regulation 536/2014 Q&A document : algorithm 2: Risk
More informationCoordinated European Animal Welfare Network (EUWelNet)
Coordinated European Animal Welfare Network (EUWelNet) Executive summary Title Executive summary of the project Coordinated European Animal Welfare Network (EUWelNet) Authors Isabelle Veissier, Inra Marek
More informationAnnual Dinner Debate 2015
The Association of European Vehicle Logistics Annual Dinner Debate 2015 Stanhope Hotel Brussels 24 th March 2015 Ship Train Compound Barge The Association of European Vehicle Logistics Opening by Costantino
More informationEUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY
EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY Health systems, medical products and innovation Medicines: policy, authorisation and monitoring STAMP 4/24 Record STAMP Commission Expert
More informationRegulatory and ethical requirements in medical devices studies. France
Regulatory and ethical in medical devices studies France SECTIONS A.Type of research SECTIONS A.Type of research We have differentiated 8 types of research: Medical device alone with CE mark use within
More informationPHARMACEUTICAL COMMITTEE SUMMARY RECORD 60 th meeting, 2 nd May 2006
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals PHARM 529 PHARMACEUTICAL COMMITTEE SUMMARY RECORD 60 th meeting, 2 nd May 2006 OPENING Mr Martin Terberger,
More informationCouncil of the European Union Brussels, 10 November 2016 (OR. en)
Conseil UE Council of the European Union Brussels, 10 November 2016 (OR. en) Interinstitutional File: 2016/0186 (COD) 13660/16 LIMITE NOTE CULT 101 AELE 77 EEE 41 CODEC 1506 From: Permanent Representatives
More informationValue of harmonized Nordic ethical evaluation of clinical trials. Mika Scheinin University of Turku, Finland Nordic Trial Alliance, Oslo 30.1.
Value of harmonized Nordic ethical evaluation of clinical trials Mika Scheinin University of Turku, Finland Nordic Trial Alliance, Oslo 30.1.2017 Nordic Trial Alliance: Mission The mission of the NordForsk
More informationCreation of a pan-european Paediatric Clinical Trials Network. Heidrun Hildebrand (Bayer) & William Treem (Janssen),
Creation of a pan-european Paediatric Clinical Trials Network Heidrun Hildebrand (Bayer) & William Treem (Janssen), 19.12.2016 IMI webinar Need for public-private collaboration Due to European Regulation,
More informationUpdate on the IMI2 Proposal to Build a Sustainable pan- European Paediatric Clinical Trials Network
Update on the IMI2 Proposal to Build a Sustainable pan- European Paediatric Clinical Trials Network William R Treem, M.D.;* Child Health Innovation and Leadership Department, Johnson and Johnson October
More informationEurordis Position on NGOs Transparency
October 2005 Eurordis Position on NGOs Transparency Eurordis believes that transparency cannot be restricted to the narrow issue of transparency on funding - a necessary but not sufficient condition of
More informationClinical Studies. Information Day, Brussels 8 July 2016
Clinical Studies Information Day, Brussels 8 July 2016 Cornelius Schmaltz Mark Goldammer Maria Saura Moreno Mila Bas Sanchez Directorate Health DG Research and Innovation Agenda I. Template 'Essential
More informationSubject: Invitation to the 12th Global Summit of National Ethics/Bioethics Committees
18/01/2018 Ref.: CL/4230 Subject: Invitation to the 12th Global Summit of National Ethics/Bioethics Committees Sir/Madam, I have the honour to invite your Government to nominate a participant to attend
More informationVacancy Notice. 1. The job (7)
09.11.2015 1(7) Vacancy Notice The European Chemicals Agency (ECHA) is launching this call for expressions of interest in order to establish a reserve list for the following temporary agent profile: Reference
More informationENVIRONMENT. Achieving CONCEPT PAPER
ASIA SIA-EUROPE ENVIRONMENT FORUM 5 TH ROUNDTABLE Achieving Urban Sustainability: Integrated Environmental Management 28-30 November Shenzhen, China CONCEPT PAPER SUMMARY A roundtable discussion among
More informationEU-RUSSIA ENERGY DIALOGUE
EU-RUSSIA ENERGY DIALOGUE Thematic Group on Energy Efficiency REPORT 2010 (SECOND HALF 2008 SECOND HALF 2010) INTRODUCTION Cooperation on energy efficiency, energy savings and renewable energy is an important
More informationABPI response to European Commission consultation on advanced therapy medicinal products
ABPI response to European Commission consultation on advanced therapy medicinal products 28 March 2013 ABPI response to European Commission consultation on the regulation of advanced therapy medicinal
More informationOECD Recommendation on the Governance of Clinical Trials
OECD Recommendation on the Governance of Clinical Trials ORGANISATION FOR ECONOMIC CO-OPERATION AND DEVELOPMENT The OECD is a unique forum where governments work together to address the economic, social
More informationInternational Transfers of Personal Data at sanofi-aventis R & D
International Transfers of Personal Data at sanofi-aventis R & D Pierre-Yves Lastic, PhD Senior Director, Standards Management & Data Privacy Sanofi-aventis R&D CONFERENCE ON INTERNATIONAL TRANSFERS OF
More informationPan European Paediatric Clinical Trials Network From idea to realization
Pan European Paediatric Clinical Trials Network From idea to realization Heidrun Hildebrand, Bayer Ag Mark Turner, University of Liverpool 2 Nordic Pediatric Conference Helsinki, May 21/22, 2018 This project
More informationE O. The EORTC Strategy for New Drug Development THE EORTC PROVIDES: The EORTC is the leading pan-european partner for high-quality clinical research
The EORTC Strategy for New Drug Development The EORTC is the leading pan-european partner for high-quality clinical research E O RT C THE EORTC PROVIDES: A NETWORK OF HIGH-QUALITY, DEDICATED CLINICAL RESEARCHERS
More informationRegulatory and ethical requirements in medical device studies. Finland
Regulatory and ethical in medical device studies Finland SECTIONS A.Type of research SECTIONS A.Type of research We have differentiated 8 types of research: Medical device alone with CE mark use within
More informationEEA resource efficiency webinar, 4 Dec 2015
EEA resource efficiency webinar, 4 Dec 2015 More from less and 2015 review of material resource efficiency policies in 31 countries Welcome - will start at 12:30 sharp Here you can adjust the size of display
More informationFinding the Balance between Clinical & Commercial Key Roles. Stewart Geary Chief Medical Officer, Senior Vice President, Eisai, Japan
IBC LIFE SCIENCES Part of: 4 TH ANNUAL Grand Copthorne Waterfront Hotel, Finding the Balance between Clinical & Commercial Key Roles Expert Faculty Include: Ajay Tiku Vice President Medical, Asia Pacific,
More informationImpact of Clinical EU Directive on the implementation of Early development studies in Europe
Impact of Clinical EU Directive on the implementation of Early development studies in Europe Alain Patat, M.D. Translational Development Wyeth Research Paris, France AGAH-Club Phase 1 1 st Syposium Strasbourg
More informationCOMMISSION OF THE EUROPEAN COMMUNITIES
COMMISSION OF THE EUROPEAN COMMUNITIES Brussels, 29.06.2005 COM(2005) 286 final REPORT FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT, THE COUNCIL, THE COMMITTEE OF THE REGIONS AND THE EUROPEAN ECONOMIC
More informationThe Situation of Investigator Initiated Trials in Europe. Dr.N.Gökbuget
The Situation of Investigator Initiated Trials in Europe Dr.N.Gökbuget Investigator Initiated Trials in Europe Difficulties and Possibilities 1. Situation for academic clinical trials after the EU directive
More informationCouncil of the European Union Brussels, 8 December 2017 (OR. en)
Council of the European Union Brussels, 8 December 2017 (OR. en) 14866/17 LEGISLATIVE ACTS AND OTHER INSTRUMTS Subject: CORLX 548 CFSP/PESC 1063 CSDP/PSDC 667 FIN 752 COUNCIL DECISION establishing Permanent
More informationCutting Red Tape The Member State point of view. Presentation by Hilde Van de Velde Bruges March 2010
Cutting Red Tape The Member State point of view Presentation by Hilde Van de Velde Bruges March 2010 The Action Programme created a momentum for reducing administrative burdens and inspired MS to launch
More informationPediatric drug development - do we need a PIP so early in development? American versus European approach
Pediatric drug development - do we need a PIP so early in development? American versus European approach Angelika Joos Executive Director, Global Regulatory Policy Merck Sharp & Dohme (Europe) Inc., Brussels
More informationMarket surveillance of medical devices
Market surveillance of medical devices A Joint Action to reinforce public health protection and medical devices monitoring by implementing joint manufacturer inspections and improving clinical process
More informationREVISION OF THE CLINICAL TRIALS DIRECTIVE 2001/20/EC UK RESPONSE TO CONCEPT PAPER
REVISION OF THE CLINICAL TRIALS DIRECTIVE 2001/20/EC UK RESPONSE TO CONCEPT PAPER Introduction This letter provides the UK Government s response to the Commission s public consultation on the proposed
More informationFACT SHEET. A CRA Perspective: The Difference between Medical Device Studies and Pharmaceutical Studies.
FACT SHEET A CRA Perspective: The Difference between Medical Device Studies and Pharmaceutical Studies Experts Providing Experts TalentSource Life Sciences is the dedicated flexible resourcing business
More informationarena that impact on clinical development
RESEARCH DEVELOPMENT Changes in the regulatory arena that impact on clinical development 23 May 2011 Agenda Voluntary Harmonisation Procedure PIP and Paediatric requirements Changes to EudraCT and European
More informationMemorandum of Understanding ON THE EUROPEAN CENTRE OF EXCELLENCE FOR COUNTERING HYBRID THREATS
Memorandum of Understanding ON THE EUROPEAN CENTRE OF EXCELLENCE FOR COUNTERING HYBRID THREATS The Signatories to this Memorandum of Understanding (hereafter the Participants ); Recalling the Joint Communication
More informationPublic Consultation on the European Solidarity Corps
Contribution ID: 94df7e58-a466-43b9-a2cd-6e6b82df0c88 Date: 30/03/2017 14:21:49 Public Consultation on the European Solidarity Corps Fields marked with * are mandatory. Introduction The European Solidarity
More informationCOMMENTS FROM EUROPABIO GENERAL COMMENTS
SUBMISSION OF COMMENTS ON DETAILED GUIDANCE FOR THE REQUEST FOR AUTHORISATION OF A CLINICAL TRIAL ON A MEDICINAL PRODUCT FOR HUMAN USE TO THE COMPETENT AUTHORITIES, NOTIFICATION OF SUBSTANTIAL AMENDMENTS
More informationWP Inspection Competence of Authorities
WP Inspection Competence of Authorities Eva G. Friberg (chair) and Steve Ebdon-Jackson 1 Action Plan Tasks: Survey on clinical competence 2012 Clinical training courses for Inspectors in UK 2014 HERCA
More informationMechanism of coordinated access to Orphan Medicinal Products. MoCA. NIHDI Belgium
Mechanism of coordinated access to Orphan Medicinal Products MoCA dr Ri DeRidder NIHDI Belgium Context The Issue: Delays and disparities in access to OMP s Decisions on Pricing and Reimbursement exclusive
More informationFirst Plenary Session CONVERGING OR DIVERGING MODELS OF HTA IN EUROPE. Jean-Luc Harousseau, MD
First Plenary Session Speaker CONVERGING OR DIVERGING MODELS OF HTA IN EUROPE Jean-Luc Harousseau, MD President and Chairman of the Board Haute Autorité de Santé (HAS) Saint-Denis La Plaine, France HTA
More informationThe European Commission s strategy on Corporate Social Responsibility (CSR) : achievements, shortcomings and future challenges
The European Commission s strategy on Corporate Social Responsibility (CSR) 2011-2014: achievements, shortcomings and future challenges Fields marked with are mandatory. 1 Introduction - Background and
More informationJanuary Summary
The Academy of Medical Sciences and the Royal Academy of Engineering joint response to the Medicine and Healthcare products Regulatory Agency s public consultation on the revision of European legislation
More informationEUROPEAN COMMISSION DIRECTORATE-GENERAL ENVIRONMENT Directorate C - Quality of Life, Water & Air
EUROPEAN COMMISSION DIRECTORATE-GENERAL ENVIRONMENT Directorate C - Quality of Life, Water & Air DIRECTORATE-GENERAL INTERNAL MARKET AND SERVICES Directorate C Public Procurement Multi-stakeholder Dialogue
More informationOfficial Journal of the European Union L 153/9
14.6.2007 Official Journal of the European Union L 153/9 COMMISSION REGULATION (EC) No 653/2007 of 13 June 2007 on the use of a common European format for safety certificates and application documents
More informationWhere next for the European Clinical Trials Directive 2001/20/EC?
ISSN 1369-9407 18 DECEMBER 2008 Where next for the European Clinical Trials Directive 2001/20/EC? The voices of stakeholders were heard in London last October and again this month in Brussels. Changes
More informationCONCEPT PAPER. ASIA-EUROPE ENVIRONMENT FORUM 4 TH ROUNDTABLE Combine or Combust! Co-operating on Chemicals and Hazardous Substances Management
ASIA-EUROPE ENVIRONMENT FORUM 4 TH ROUNDTABLE Combine or Combust! Co-operating on Chemicals and Hazardous Substances Management 30 November-1 December Brussels, Belgium CONCEPT PAPER SUMMARY A roundtable
More informationEU Policy on Waste-to-Energy
EU Policy on Waste-to-Energy an overview ISWA Beacon Conference 25-26 October 2007, Malmö, Sweden Dr. Ella Stengler CEWEP - Managing Director Waste-to-Energy in Europe in 2005 Waste-to-Energy Plants in
More informationPublic Consultation on a proposal for a mandatory Transparency Register
Case Id: 2963fe2f-f4f5-4f55-8698-bc26718599b0 Date: 01/06/2016 18:24:12 Public Consultation on a proposal for a mandatory Transparency Register Fields marked with are mandatory. Public Consultation on
More informationHow will new EU countries ensure that their QP standards are acceptable?
How will new EU countries ensure that their QP standards are acceptable? Faculty of Pharmacy, University of Belgrade 15.-16.4., 2010 dr. Mila Božić In the new EU countries (former CADREAC) In many aspects
More informationMin Shu Waseda University. 2013/10/15 European Public Policy-Week 3 1
Min Shu Waseda University 2013/10/15 European Public Policy-Week 3 1 The Institutional Structure of the EU European Commission Council of Ministers European Council European Parliament European Central
More informationPosition Paper. Executive Summary
Position Paper Status: Final Date of document: 10.10.2017 Hospital Exemption for Advanced Therapy Medicinal Products (ATMPs): greater transparency needed in order to improve patient safety and access to
More informationEUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Public health and Risk assessment Pharmaceuticals Brussels, 01 June 2010 SANCO/C/8/SF/dn D(2010) 326199 THE RULES GOVERNING MEDICINAL PRODUCTS
More informationRevising the Pharmaceutical Landscape in the EU
Revising the Pharmaceutical Landscape in the EU The Industry Perspective Dr. Christine-Lise Julou June 2008 1 Revising the pharmaceutical landscape in Europe Preamble New Legislation Other regulatory initiatives
More informationEngagement with stakeholders
Engagement with stakeholders 2 nd International Awareness Session - The EU medicines regulatory system and the European Medicines Agency Presented by Juan Garcia Burgos and Marie-Helene Pinheiro on 8 March
More informationCAN GDPR WORK FOR HEALTH SCIENTIFIC RESEARCH? BRUSSELS OCTOBER 22 ND CIPL EFPIA FPF EXECUTIVE SUMMARY
CAN GDPR WORK FOR HEALTH SCIENTIFIC RESEARCH? BRUSSELS OCTOBER 22 ND 2018 - CIPL EFPIA FPF EXECUTIVE SUMMARY Despite many actors good intentions, the health research sector has so far survived GDPR rather
More informationReusable packaging in Europe: Boosting Business and Closing the Loop
INVITATION The European Association of Beverage Wholesalers (CEGROBB), the Environmental Action Germany (Deutsche Umwelthilfe), the Association of Small and Independent Breweries in Europe (S.I.B.) and
More informationEUCROF Presentation. EMA Roundtable meeting with stakeholders on the 10-year anniversary of the SME Office. 27 November 2015 London
EUCROF Presentation EMA Roundtable meeting with stakeholders on the 10-year anniversary of the SME Office 27 November 2015 London Dr. Stefano Marini, MD EUCROF President European Contract Research Organization
More informationCitation for the original published paper (version of record):
http://www.diva-portal.org Postprint This is the accepted version of a paper published in Patient. This paper has been peer-reviewed but does not include the final publisher proof-corrections or journal
More informationWaste prevention in Europe. European Environment Agency
Waste prevention in Europe Özgür Saki European Environment Agency The European Environment Agency An EU institution situated in Copenhagen since 1994 Provides the information necessary to enable policy
More informationPatient Involvement in HTA: An example of How and Why. 26 September 2017
Patient Involvement in HTA: An example of How and Why 26 September 2017 Background A pharma company launching a new drug commissioned an HTA evaluation to an Academic Institution in Italy Patient Experts
More informationFACILITATION OF THE ENTRY INTO FORCE AND HARMONIZED INTERPRETATION OF THE HNS PROTOCOL, 2010
E LEGAL COMMITTEE 102nd session Agenda item 3 LEG 102/3/2 2 March 2015 Original: ENGLISH FACILITATION OF THE ENTRY INTO FORCE AND HARMONIZED INTERPRETATION OF THE HNS PROTOCOL, 2010 Report of a Workshop
More information